Measuring CXCL5 protein levels in people with lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study looks at a protein called CXCL5 in the blood of people with lupus and whether its level relates to how active the disease is. It is a simple blood test that might help doctors understand lupus activity better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You must have been diagnosed with systemic lupus erythematosus (SLE, often called lupus)
- You cannot have other autoimmune diseases
- You cannot have cancer or an active infection
- You cannot be pregnant or breastfeeding
- You must be willing to participate in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called CLN-978, given as a shot under the skin, that targets a protein on certain immune cells (B cells) to try to calm overactive immune activity in lupus. The goal is to see if it can reduce lupus symptoms for people whose disease has not been controlled by other treatments.
This study looks at whether two blood markers (AGR and PNI) can help track how active lupus is. You may be eligible if you have lupus and are not pregnant or have other serious health conditions.
This study looks at whether two blood test markers (called T IgG and T IgM) can help doctors understand how active your lupus is and how much damage the disease has caused. If you join, your blood will be tested, and the results may help guide your treatment.
This study looks at blood test results in children and teenagers with lupus to see if they relate to how active the disease is or if it has caused long-term damage. It may help doctors better understand the disease.
This study looks at a gene that may be linked to lupus. It aims to understand how this gene affects the disease, which could help improve future treatments.
This study looks at whether certain substances in the blood, such as uric acid, homocysteine, and interleukin-17, are higher in people with lupus-related kidney disease compared to healthy individuals. It aims to find new ways to monitor or understand the condition better.
Hear when a new SLE (Systemic Lupus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.